[go: up one dir, main page]

WO2016001208A1 - Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate - Google Patents

Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate Download PDF

Info

Publication number
WO2016001208A1
WO2016001208A1 PCT/EP2015/064811 EP2015064811W WO2016001208A1 WO 2016001208 A1 WO2016001208 A1 WO 2016001208A1 EP 2015064811 W EP2015064811 W EP 2015064811W WO 2016001208 A1 WO2016001208 A1 WO 2016001208A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
total amount
pharmaceutical
surfactant
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/064811
Other languages
English (en)
Inventor
Sergio Arroyo Hidalgo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galenicum Health SL
Original Assignee
Galenicum Health SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galenicum Health SL filed Critical Galenicum Health SL
Priority to EP15731621.7A priority Critical patent/EP3160450A1/fr
Publication of WO2016001208A1 publication Critical patent/WO2016001208A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to stable pharmaceutical compositions of abiraterone acetate or a pharmaceutically acceptable salt thereof, in the form of immediate release tablets, to a process for the manufacture of said stable pharmaceutical compositions and to the use thereof in the treatment of cancer.
  • Abiraterone is a selective inhibitor of 17a-hydroxylase/C17,20 lyase (CYP17A1 ), an enzyme which is known to be essential for the biosynthesis of androgens and oestrogens.
  • CYP17 is expressed in testicular, adrenal, and prostatic tumor tissues.
  • Said enzyme complex catalyzes the conversion of pregnenolone and progesterone to their 17a-hydroxy derivatives by its 17a-hydroxylase activity, and the subsequent formation of the androgens dehydroepiandrosterone (DHEA) and androstenedione, by its C17,20 lyase activity.
  • DHEA dehydroepiandrosterone
  • the androgens DHEA and androstenedione are precursors of testosterone.
  • inhibition of CYP17 activity by abiraterone decreases circulating levels of testosterone and other androgens in cancer patients.
  • Abiraterone is poorly bioavailable. Therefore, the prodrug abiraterone acetate which is rapidly deacetylated to abiraterone in vivo is used.
  • Abiraterone acetate (INN, CB7630; JNJ-212082; Zytiga®) is a pregnenolone analog used in castration-resistant prostate cancer (CRPC).
  • Abiraterone acetate i.e 3 ⁇ -17-(3- pyridinyl)androsta-5,16-dien-3-yl acetate
  • Abiraterone acetate was first approved by the FDA in April 201 1 for the treatment of patients with metastatic CRPC, who have received prior chemotherapy containing docetaxel. Abiraterone acetate was launched in USA and Europe by Johnson & Johnson under the tradename Zytiga®. The chemical structure of abiraterone acetate, as commercially available, is shown in formula (1 ):
  • Abiraterone acetate is a white to off-white, non-hygroscopic, crystalline powder. Its molecular formula is C25H 33 NO2 and it has a molecular weight of 391.55 g/mol. Abiraterone acetate is practically insoluble in water.
  • Abiraterone acetate (Zytiga®) is being marketed as an immediate-release tablet containing 250 mg of abiraterone acetate.
  • a daily dose of 1000 mg abiraterone acetate is administered once daily in combination with 5 mg prednisone twice daily for the treatment of patients with metastatic castration-resistant prostate cancer.
  • ZYTIGA® is administered in a fasted state in an attempt to minimise the erratic and unpredictable bioavailability demonstrated in the fed state.
  • ZYTIGA® has poor bioavailability in fasted subjects and must therefore be administered at a very high daily dose.
  • Administration of a drug composition with food may change its bioavailability by affecting either the drug substance or the composition in which the drug substance is formulated.
  • Food can alter the bioavailability of a drug by different mechanisms, including: delayed gastric emptying; stimulation of bile flow; changed gastrointestinal pH; increased visceral blood flow; changed luminal metabolism; and physical or chemical interactions of food components with the drug compound or one or more excipients contained in the composition.
  • food induced changes in gut physiology can contribute to these effects, or there may be instability of the drug substance.
  • BCS Biopharmaceutics Classification System
  • drugs are classified on the basis of the parameters solubility, permeability and dissolution.
  • BCS class IV compounds exhibit low permeability and low solubility. Those compounds have a poor bioavailability. That is, their bioavailability is limited by both solvation rate and permeability. Usually they are not well absorbed over the intestinal mucosa and a high variability is expected, which makes them particularly difficult to administer orally. These factors alone or in combination may contribute to the observed large food effect and intra-subject and inter-subject variability of this drug substance in its current commercial presentation.
  • abiraterone acetate poses particular formulation problems, not only because of its erratic bioavailability, but also because of its poor bioavailability in fasted subjects, it must be administered at such a high daily dose (1000 mg/day).
  • the present invention provides stable pharmaceutical compositions of abiraterone acetate or a pharmaceutically acceptable salt thereof in the form of immediate release tablets. Furthermore, the present invention provides a pharmaceutical composition in the form of an immediate release tablet comprising abiraterone acetate, which has an improved solubility of the drug resulting in good bioavailability and efficacy of the pharmaceutical composition. Said pharmaceutical compositions are able to reduce the intra- and inter-subject variability when abiraterone acetate is administered due to its low solubility and low permeability.
  • compositions of the present invention offer the additional benefit of a simple, robust and reproducible process that helps to reduce the intra- and inter-subject variability of abiraterone acetate. It has been found that a specific particle size together with a specific amount of surfactant can be used to stabilize pharmaceutical compositions of abiraterone acetate or a pharmaceutically acceptable salt thereof, especially immediate release tablets manufactured by wet granulation.
  • the stable immediate release tablets as disclosed herein are uniform in content. Moreover, the batches show good flowability.
  • the present invention relates to a pharmaceutical composition in the form of immediate release tablets comprising abiraterone acetate or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition comprises between 2 and 8 % w/w of surfactant in respect of the total amount of the pharmaceutical composition and/or the D50 of abiraterone acetate is between 3 to 10 microns as measured by laser diffraction spectroscopy and/or the D90 of abiraterone acetate is less than 20 microns as measured by laser diffraction spectroscopy.
  • the particle size distribution of the abiraterone acetate was analysed by laser diffraction spectroscopy using a Malvern Mastersizer 2000 hydro2000-SM particle size analyzer with water and polysorbate 80 as dispersant, stir speed of 2500 rpm, cyclomixture during one minute, sonication during 30 sec, sample concentration 100 mg/20 ml and measurement time 12 seconds.
  • Pharmaceutical compositions of the prior art comprising abiraterone acetate use low quantities of surfactant, ie. CN102743393 discloses the use of 0.1 % of SDS (sodium lauryl sulfate).
  • composition refers to a finished dosage formulation, which contains the active agent abiraterone acetate and which is in the form in which it can be marketed for use.
  • An immediate release tablet as herein disclosed has to be understood as a tablet having a dissolution performance such as 60 % or more of the active agent contained in said pharmaceutical composition dissolves within 60 minutes (min).
  • the immediate release composition as herein disclosed releases at least 80 % of the active agent in 60 minutes.
  • the pharmaceutical composition as herein disclosed releases at least 80 % of the active agent in 45 min, preferably in 35 min and more preferably in 30 min.
  • the pharmaceutical composition as herein disclosed releases at least 80 % of the active agent in 30 min and at least a 95 % of the active agent in 60 min.
  • the pharmaceutical composition comprises between 2 and 8 % w/w of surfactant in respect of the total amount of the pharmaceutical composition and the D50 of abiraterone acetate is between 3 to 10 microns as measured by laser diffraction spectroscopy and the D90 of abiraterone acetate is less than 20 microns as measured by laser diffraction spectroscopy.
  • the pharmaceutical composition comprises between 3 and 6 % w/w of surfactant in respect of the total amount of the pharmaceutical composition, preferably between 3.5 and 5 % w/w of surfactant in respect of the total amount of the pharmaceutical composition, more preferably 4 % w/w of surfactant in respect of the total amount of the pharmaceutical.
  • the poor water solubility and low permeability of the BCS class IV compounds entails a further challenge in formulating abiraterone acetate in a tablet with good bioavailability.
  • One method of formulating such compounds is by the addition of a surfactant which enhances the solubility of the drug.
  • surfactant refers to a pharmaceutically acceptable excipient having hydrophobic and hydrophilic units which are capable of solubilizing a non-water soluble drug in water. Any of a variety of surfactants selected from a group consisting of anionic, amphoteric, nonionic, cationic surfactants, and combinations of two or more thereof may be used in accord with the present invention.
  • nonionic surfactant refers to an ionic surfactant in which the hydrophilic portion of the surfactant carries no charge.
  • nonionic surfactants useful in the present invention are polyoxyethylene derivatives of polyol esters, long chain alkyl glucosides or polyglucosides, PEG-80 sorbitan laurate, polysorbates (e. g., polysorbate 80, polysorbate 40, polysorbate 20), and the like.
  • an ionic surfactant not only can act as an aid to drug solubilisation, it may also generate an environment around the drug substance that mimics the environment created by the release of endogenous or natural surfactants such as ionic surfactants as part of the process of digestion after the intake of food. It is believed that ionic surfactants may interact with the drug substance to form micelles that in turn interact with the unstirred water layer (UWL)- a bicarbonate-rich layer of mucus that maintains pH levels at around 7 at the vill surface - and the intestinal mucosa, to enhance absorption therethrough.
  • UWL unstirred water layer
  • the surfactant is selected from nonionic, ionic and mixtures thereof; preferably is an ionic surfactant.
  • the surfactant is an ionic surfactant selected from cationic, anionic, zwitterionic and mixtures thereof.
  • the surfactant is an anionic surfactant.
  • Suitable anionic surfactants includes sodium lauryl sulphate, sodium palmate, sodium stearate and triethanolamine lauryl sulphate.
  • the anionic surfactant is sodium lauryl sulphate.
  • the sodium lauryl sulphate functions as a wetting agent and helps solubilisation.
  • the pharmaceutical composition comprises between 3.5 and 5 % w/w of sodium lauryl sulfate in respect of the total amount of the pharmaceutical composition, preferably about 4 % w/w of sodium lauryl sulfate in respect of the total amount of the pharmaceutical composition.
  • the pharmaceutical composition of the present invention is stable.
  • stable refers to a pharmaceutical composition comprising abiraterone acetate wherein the total content of impurities originating from the decomposition of abiraterone acetate does not exceed 5 % area, preferably 3 % area, more preferably 2 % area and most preferably 1 % area determined by liquid chromatography (HPLC) at 237 nm if such a composition is stored for 2 months at 40°C and 75 % relative humidity (RH).
  • HPLC liquid chromatography
  • the pharmaceutical composition as herein disclosed comprises excipients such as a filler, a lubricant, a disintegrant, a binder or glidant
  • these excipients are pharmaceutically acceptable.
  • pharmaceutically acceptable indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • filler refers to pharmaceutically acceptable excipients which are added to the bulk volume of the active agent making up the solid composition. As a result, the size of the solid composition increases, which makes its size suitable for handling. Fillers are convenient when the dose of drug per solid composition is low and the solid composition would otherwise be too small.
  • said pharmaceutical composition comprises at least a filler.
  • the total amount of filler or fillers present in the pharmaceutical composition ranges from 30 to 65 % w/w in respect of the total amount of the pharmaceutical composition. More preferably, the total amount of filler or fillers present in the pharmaceutical composition ranges from 25 to 55 % by weight in respect of the total amount of the pharmaceutical composition.
  • said pharmaceutical composition further comprises a filler selected from dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dihydrate, lactose, mannitol, microcrystalline cellulose, starch, tribasic calcium phosphate, and mixtures thereof.
  • a filler selected from dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dihydrate, lactose, mannitol, microcrystalline cellulose, starch, tribasic calcium phosphate, and mixtures thereof.
  • the pharmaceutical composition comprises microcrystalline cellulose, lactose or mixtures thereof.
  • disintegrant means a substance or a mixture of substances added to a tablet to facilitate its breakup or disintegration after administration.
  • said pharmaceutical composition comprises at least a disintegrant.
  • the total amount of disintegrant or disintegrants present in the pharmaceutical composition ranges from 1 to 15 % w/w in respect of the total amount of the pharmaceutical composition. More preferably, the total amount of disintegrant or disintegrants present in the pharmaceutical composition ranges from 5 to 10 % by weight in respect of the total amount of the pharmaceutical composition.
  • said pharmaceutical composition comprises at least a disintegrant selected from water-soluble disintegrants, disintegrant selected from starch, pregelatinized starch, sodium starch glycolate, povidone, croscarmellose sodium, crospovidone, microcrystalline cellulose, and mixtures thereof.
  • the pharmaceutical composition comprises croscarmellose sodium.
  • binder as used herein is defined as an agent able to bind particles which cannot be bound only by a simple compression force.
  • the binder may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
  • said pharmaceutical composition comprises at least a binder.
  • the total amount of binder or binders present in the pharmaceutical composition ranges from 1 to 10 % w/w in respect of the total amount of the pharmaceutical composition. More preferably, the total amount of binder or binders present in the pharmaceutical composition ranges from 2 to 8 % by weight in respect of the total amount of the pharmaceutical composition.
  • said pharmaceutical composition further comprises a binder selected from starch, maltodextrin, gelatin, natural and synthetic gums, cellulose and its derivatives, polyvinyl alcohol, polyvinylpyrrolidone and mixtures thereof.
  • a binder selected from starch, maltodextrin, gelatin, natural and synthetic gums, cellulose and its derivatives, polyvinyl alcohol, polyvinylpyrrolidone and mixtures thereof.
  • the pharmaceutical composition comprises polyvinylpyrrolidone.
  • lubricant means a substance that reduces friction between the composition of the present invention and the surfaces of the apparatus used to compact the composition into a compressed form. The function of a lubricant in the product formulation is to prevent powder from sticking to the punches, dies, and other metal components of the tablet press.
  • said pharmaceutical composition comprises at least a lubricant.
  • the total amount of lubricant or lubricants present in the pharmaceutical composition ranges from 0.5 to 5 % w/w in respect of the total amount of the pharmaceutical composition. More preferably, the total amount of lubricant or lubricants present in the pharmaceutical composition ranges from 1 .2 to 2 % by weight in respect of the total amount of the pharmaceutical composition. The inventors have surprisingly found that the such quantities of lubricant help to avoid the tablet sticking during the process.
  • said pharmaceutical composition comprises at least a lubricant selected calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, or mixtures thereof.
  • the pharmaceutical composition comprises magnesium stearate.
  • glidant means a substance which improves the flow characteristics of powder mixtures in the dry state.
  • said pharmaceutical composition comprises at least a glidant.
  • the total amount of glidant or glidants present in the pharmaceutical composition ranges from 0.08 to 3 % w/w in respect of the total amount of the pharmaceutical composition. More preferably, the total amount of glidant or glidants present in the pharmaceutical composition ranges from 0.05 to 1 .5 % w/w in respect of the total amount of the pharmaceutical composition.
  • said pharmaceutical composition comprises at least a glidant selected from the group consisting of colloidal silicon dioxide, talc, starch, starch derivatives, and mixtures thereof.
  • the pharmaceutical composition comprises colloidal silicon dioxide.
  • the pharmaceutical composition comprises from 100 to 400 mg of active agent per unit dose.
  • the pharmaceutical composition comprises about 250 mg of active agent per unit dose.
  • the unit dose or unit dosage may be in the form of a tablet, capsule, sachet, etc. referred to herein as a "unit dosage form”.
  • the pharmaceutical compositions are manufactured by wet granulation techniques.
  • pharmaceutical granulate or “granulate” or “granular component” as used herein refers to the part of the pharmaceutical composition that has been obtained by granulating a powder into larger particles herein called granules.
  • granulation refers to the process of agglomerating powder particles into larger agglomerates (i.e. granules) that contain the active pharmaceutical ingredient.
  • granulation includes wet granulation techniques.
  • wet granulation refers to any process comprising the steps of addition of a liquid to powder starting materials, preferably kneading, and drying to yield a solid dosage form.
  • composition in the form of tablet of the first aspect comprises:
  • an intragranular portion comprising abiraterone acetate and at least a surfactant, at least a binder, at least a filler, at least a disintegrant, and;
  • an extragranular portion comprising at least a lubricant and at least a glidant.
  • the disintegrant can be incorporated either intragranular, extragranular or it can be distributed both intra and extragranular. According to the literature and the state of the art, in general the extragranular incorporation seemed to favour the dissolution (Gordon MS, Chowhan ZT. Effect of mode of croscarmellose sodium incorporation on tablet dissolution and friability. J Pharm Sci 1990; 79(1 ); 43-7). So, it would be expected that using disintegrant in extragranular incorporation gave faster disintegration times than either intragranular or mix of intra- and extra- granular disintegrant.
  • the inventors have found that incorporating the disintegrant in the pharmaceutical composition of abiraterone, faster disintegration times were obtained and the release of the drug was at least 80 % of the active agent in 30 min and at least a 95 % of the active agent in 60 min.
  • composition in the form of tablet of the first aspect comprises:
  • an intragranular portion comprising abiraterone acetate, sodium lauryl sulfate, polyvinylpyrrolidone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and; ii) an extragranular portion comprising colloidal silicon dioxide and magnesium stearate.
  • the pharmaceutical composition has an average hardness between 100 and 200 N, preferably between 120 and 180 N, more preferably between 130 and 160 N, and even more preferably between 135 and 145 N.
  • the inventors found that the critical steps in the manufacturing process were wet granulation, drying and compression.
  • the inventors have surprisingly found that simple, robust and reproducible process is obtained adding a portion of the binder in the solution and another portion in the comprising intragranular mixture.
  • the present invention relates to a process for the manufacture of the pharmaceutical composition as defined in any of the preceding claims, comprising the following steps:
  • step (iii) granulating the mixture obtained in step (ii) with the solution of step (i) by a wet granulation process to produce a granulate;
  • step (iv) optionally, performing a sieving of the granulate obtained in step (iv);
  • step (iv) blending the granulate of step (iv) with at least one extragranular excipient;
  • step (vi) adding at least one lubricant to the blended composition of step (vi);
  • step (viii) compressing the blended composition of step (vii) to obtain a tablet composition.
  • the intragranular composition comprises abiraterone acetate or a pharmaceutically acceptable salt thereof, a first intragranular filler, optionally a second intragranular filler, an intragranular disintegrant, an intragranular surfactant and an intragranular binder; and the extragranular composition comprises an extragranular glidant and an extragranular lubricant.
  • the process comprises the following steps:
  • step (iii) granulating the mixture obtained in step (ii) with the solution of step (i) by a wet granulation process to produce a granulate;
  • step (iv) optionally, performing a sieving of the granulate obtained in step (iv);
  • step (iv) blending the granulate of step (iv) with at least one extragranular excipient;
  • step (vi) adding at least one lubricant to the blended composition of step (vi);
  • step (viii) compressing the blended composition of step (vii) to obtain a tablet composition.
  • the step (iv) is performed to an endpoint up to 2.5 % w/w of water content in respect of the total amount of the granulate.
  • the drying is carried out in a fluid bed at an input temperature between 30 and 50 °C.
  • the tablets are compressed in order to have an average hardness between 100 and 200 N, preferably between 120 and 180 N, more preferably between 130 and 160 N, and even more preferably between 135 and 145 N.
  • the present invention relates to the pharmaceutical composition obtained by the process of the second aspect.
  • the present invention relates to a pharmaceutical batch comprising at least 20,000 units of the pharmaceutical composition of the first or third aspect.
  • the pharmaceutical batch comprises at least 50,000 units.
  • the content of abiraterone acetate or the pharmaceutically acceptable salt thereof is uniform.
  • the tablets are packaged in a blister pack of aluminium/PVC or aluminium/aluminium or in a high density polyethylene (HDPE) bottle.
  • the pharmaceutical composition as herein disclosed are packaged in a high density polyethylene (HDPE) bottle.
  • the HDPE bottle as herein disclosed has a polypropylene child-resistant closure.
  • blister or bubble pack refers to a sheet in a package construction with recesses designed to hold dosage forms.
  • the blisters are then hermetically sealed using flat strips of appropriate thermomoldable materials (plastics, aluminum, paper), which represent the frangible element through which it is then possible to remove the product.
  • An aluminium/PVC blister refers to a blister the thermomoldable material is from PVC and the backing is a lidding seal of aluminium foil.
  • Blister packs are commonly used as unit-dose packaging for pharmaceutical tablets, capsules or lozenges. Blister packs can provide barrier protection for shelf life requirements, and a degree of tamper resistance.
  • batch refers to a specific quantity of a drug or other material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture.
  • a batch in the case of a drug product produced by continuous process, is a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits (Code of Federal Regulations Title 21 , Food and Drug Administration department of Health and Human Services, Subchapter C, Section 210.3 (b) (2) and (10)).
  • pharmaceutical batch refers to a batch as defined above of a pharmaceutical composition manufactured in accordance with the principles and guidelines of Good Manufacturing Practice (GMP) at an industrial scale and which is intended for commercialization (Directive 91/356/EEC).
  • GMP Good Manufacturing Practice
  • the pharmaceutical composition may be manufactured at laboratory scale, not necessarily following GMP and not intended for commercialization.
  • the pharmaceutical composition may also be manufactured for validation, following GMP.
  • a batch of a pharmaceutical composition which is manufactured for validation is called "pilot batch”.
  • Each pharmaceutical batch of finished product must fulfil the regulatory requirements of the corresponding Medicine Agency before being released for sale or supply, such as impurities thresholds and stability data.
  • uniform refers to the content of the active ingredient in the tablets of a pharmaceutical batch has to be homogeneous. According to the FDA criteria, uniformity is considered as achieving 90-1 10 % potency of the theoretical strength with a relative standard deviation (RSD) of less than 5 % for all samples (Guidance for Industry ANDA's: Blend Uniformity Analysis, published August 1999).
  • active ingredient refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates and solvates of the compound and the prodrugs.
  • a fifth aspect of the present invention relates to the pharmaceutical composition of the first or third aspect or the pharmaceutical batch of the fourth aspect, for use in the treatment of cancer, preferably metastatic prostate cancer.
  • a sixth aspect of the present invention relates to a cardboard box with a patient information leaflet comprising at least one unit of the pharmaceutical composition of the first or third aspect.
  • a seventh aspect of the present invention relates to a method for preparing a pharmaceutical dossier to obtain the marketing authorization of pharmaceutical composition of the first or third aspect comprising the following steps:
  • step (iii) providing the compiled results of step (iii) in a data carrier.
  • the term "pharmaceutical dossier” to obtain the marketing authorization refers to a dossier with data proving that the drug has quality, efficacy and safety properties suitable for the intended use, additional administrative documents, samples of finished product or related substances and reagents necessary to perform analyzes of finished product as described in that dossier.
  • the present invention relates to a data carrier comprising the compiled results of a pharmaceutical dossier obtained by the method of the seventh aspect.
  • said data carrier is selected from the group consisting of a digital data carrier such as CD, DVD, USB, hard drive; and paper.
  • data carrier refers to a device for recording (storing) information (data). The recording can be done using virtually any form of energy.
  • a storage device may hold information, process information, or both. Most often the term is used with computers.
  • Data carrier can permanently hold data, like files.
  • FIG. 1 immediate release dissolution profile. Percentage of the active agent dissolved over time in minutes for example 1 of the present invention, at 0.25% SLS in 56.5 mM phosphate buffer, pH 4.5.
  • Example 1 Abiraterone acetate tablet composition
  • Example 2 Manufacture of abiraterone acetate tablets of example 1 by wet granulation
  • step (3) The granulation solution prepared in step (1 ) was added to the blend of step (2) and kneaded for 10 minutes.
  • step (3) The granulate of step (3) was dried in a fluid bed at 37 °C.
  • the particle size distribution of the abiraterone acetate was analysed by laser diffraction spectroscopy using a Malvern Mastersizer 2000 hydro2000-SM particle size analyzer.
  • the particle size distribution was D50 of 4.53 microns and D90 of 10.60 microns.
  • the amount of water of the pharmaceutical compositions as herein disclosed was measured by loss on drying (LOD) using a Halogen Moisture Analyzer.
  • the water content of the granulate in the step (4) of the process described above was less than 2.5 %.
  • Example 5 Abiraterone acetate tablet compositions. Comparative example having disintegrant intragranular with disintegrant extragranular.
  • Example 5a was manufactured following the process described in Example 2.
  • Example 5b Manufacture of abiraterone acetate tablets of example 5b with disintegrant added extragranular (1 ) A portion of povidone (K29/K32) and sodium iauryi sulfate was dissolved in purified water using a magnetic agitator.
  • step (3) The granulation solution prepared in step (1 ) was added to the blend of step (2) and kneaded for 10 minutes.
  • step (3) The granulate of step (3) was dried in a fluid bed at 37 °C.
  • the average hardness of the pharmaceutical compositions as herein disclosed was measured using a tablet hardness tester Pharma Test PTB 1 1 1 E-500.
  • the average hardness of the tablet is between 130 and 160 N. This hardness has shown the best immediate release dissolution profiles, namely at least 80 % of the active agent is released in 45 min.
  • Dissolution test of abiraterone (% abiraterone) was determined at 60 min using method USP Apparatus: II (Paddles), speed: 50 r.p.m. medium: 0.25 % sodium lauryl sulfate in 56.5 mM phosphate buffer, pH 4.5 and wavelength 237 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques stables d'acétate d'abiratérone ou un sel pharmaceutiquement acceptable de celles-ci, sous forme de comprimés à libération immédiate, un procédé pour la fabrication desdites compositions pharmaceutiques stables et l'utilisation de celles-ci dans le traitement du cancer.
PCT/EP2015/064811 2014-06-30 2015-06-30 Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate Ceased WO2016001208A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15731621.7A EP3160450A1 (fr) 2014-06-30 2015-06-30 Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14174996 2014-06-30
EP14174996.0 2014-06-30
EP15151083.1 2015-01-14
EP15151083 2015-01-14

Publications (1)

Publication Number Publication Date
WO2016001208A1 true WO2016001208A1 (fr) 2016-01-07

Family

ID=53488345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/064811 Ceased WO2016001208A1 (fr) 2014-06-30 2015-06-30 Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate

Country Status (2)

Country Link
EP (1) EP3160450A1 (fr)
WO (1) WO2016001208A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020026126A1 (fr) 2018-07-31 2020-02-06 Richter Gedeon Nyrt. Compositions pharmaceutiques stables comprenant de l'acétate d'abiratérone et leur procédé de préparation
WO2020126017A1 (fr) 2018-12-20 2020-06-25 Pharmaceutical Oriented Services Ltd Forme posologique contenant de l'acétate d'abiratérone
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2020223154A1 (fr) * 2019-05-01 2020-11-05 resTORbio, Inc. Procédés d'amélioration de la réponse immunitaire
WO2021224471A1 (fr) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Formulations pharmaceutiques d'acétate d'abiratérone et de niraparib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (fr) 1992-03-31 1993-10-14 British Technology Group Ltd. Steroïdes substitues-17 utiles pour le traitement du cancer
WO1995009178A1 (fr) 1993-09-30 1995-04-06 British Technology Group Limited Synthese de steroides a base de 17-(3-pyridyl)
WO2006021777A1 (fr) 2004-08-24 2006-03-02 Btg International Limited Procede de preparation de 17-0-vinyltriflates comme intermediaires
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2013164473A1 (fr) * 2012-05-04 2013-11-07 Jagotec Ag Composition pharmaceutique comprenant l'acétate d'abiratérone
CN103446069A (zh) * 2012-05-29 2013-12-18 重庆医药工业研究院有限责任公司 一种阿比特龙的口服固体组合物及其制备方法
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (fr) 1992-03-31 1993-10-14 British Technology Group Ltd. Steroïdes substitues-17 utiles pour le traitement du cancer
WO1995009178A1 (fr) 1993-09-30 1995-04-06 British Technology Group Limited Synthese de steroides a base de 17-(3-pyridyl)
WO2006021777A1 (fr) 2004-08-24 2006-03-02 Btg International Limited Procede de preparation de 17-0-vinyltriflates comme intermediaires
WO2013164473A1 (fr) * 2012-05-04 2013-11-07 Jagotec Ag Composition pharmaceutique comprenant l'acétate d'abiratérone
CN103446069A (zh) * 2012-05-29 2013-12-18 重庆医药工业研究院有限责任公司 一种阿比特龙的口服固体组合物及其制备方法
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Assessment Report For Zytiga (abiraterone)", EUROPEAN MEDICINES AGENCY - CHMP ASSESSMENT REPORT, 21 July 2013 (2013-07-21), pages 1 - 78, XP055205316, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002321/WC500112860.pdf> [retrieved on 20150729] *
GORDON M S ET AL: "EFFECT OF THE MODE OF CROSCARMELLOSE SODIUM INCORPORATION ON TABLETDISSOLUTION AND FRIABILITY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 79, no. 1, January 1990 (1990-01-01), pages 43 - 47, XP000101615, ISSN: 0022-3549, DOI: 10.1002/JPS.2600790111 *
GORDON MS; CHOWHAN ZT: "Effect of mode of croscarmellose sodium incorporation on tablet dissolution and friability", J PHARM SCI, vol. 79, no. 1, 1990, pages 43 - 7
GUIDANCE FOR INDUSTRY ANDA'S: BLEND UNIFORMITY ANALYSIS, August 1999 (1999-08-01)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2020026126A1 (fr) 2018-07-31 2020-02-06 Richter Gedeon Nyrt. Compositions pharmaceutiques stables comprenant de l'acétate d'abiratérone et leur procédé de préparation
WO2020126017A1 (fr) 2018-12-20 2020-06-25 Pharmaceutical Oriented Services Ltd Forme posologique contenant de l'acétate d'abiratérone
WO2020223154A1 (fr) * 2019-05-01 2020-11-05 resTORbio, Inc. Procédés d'amélioration de la réponse immunitaire
WO2021224471A1 (fr) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Formulations pharmaceutiques d'acétate d'abiratérone et de niraparib
CN115515583A (zh) * 2020-05-08 2022-12-23 詹森药业有限公司 醋酸阿比特龙和尼拉帕尼的药物配制品

Also Published As

Publication number Publication date
EP3160450A1 (fr) 2017-05-03

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
CN102056589B (zh) 包含bibw 2992的固体药物制剂
WO2016001208A1 (fr) Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate
WO2015032873A1 (fr) Compositions pharmaceutiques à charge élevée comprenant de l&#39;acétate d&#39;abiratérone
EP3156048A1 (fr) Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate
JP2021532193A (ja) 生物学的に利用可能な経口剤形
EP2514422B1 (fr) Préparation du teneligliptine à élution stabilisée
SG183449A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP4404918A1 (fr) Formes posologiques compressibles à dose élevée fabriquées par enrobage à l&#39;état fondu et granulation à l&#39;état fondu simultanés de principes pharmaceutiques actifs
HK40063384A (en) Solid dosage forms of palbociclib
EP3041462A1 (fr) Compositions pharmaceutiques à charge élevée comprenant de l&#39;acétate d&#39;abiratérone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15731621

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015731621

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015731621

Country of ref document: EP